US Election: Impacts on Biosimilars and Generics
With Donald Trump returning to the presidency, significant policy changes may lie ahead, particularly affecting the healthcare sector. The Trump administration presents opportunities and challenges for the biosimilars and generics industry. Here’s an impartial look at what his leadership might mean for this critical market: Potential Benefits Streamlined FDA Approvals Trump has historically advocated for
US Election: Impacts on Biosimilars and Generics Read More »